Kathryn Nichol

Vagus nerve stimulation therapy in Lennox-Gastaut syndrome (severe childhood epilepsy): plain language summary of a 2-year study

Paul D. Lyons, James W. Wheless, Ryan Verner, Kore Liow et autres

Plain Language SummaryWhat is this summary about?Lennox-Gastaut syndrome (LGS) is a neurological condition associated with severe epilepsy in young children, a loss of developmental skills and abilities, multiple seizure types, and often a poor response to antiseizure medications. One potential approach to …

gb, us, hr (code pays fourni par la source)

Effects of ageing and exercise training on cerebrovascular vasomotor reactivity, depressive behaviour and the hippocampal transcriptome

Britton Scheuermann, Kathryn Nichol, Cathy W. Levenson, Kiana M. Schulze et autres

The ageing global population is experiencing an increased prevalence of cerebrovascular diseases, such as stroke and dementia. This highlights a need for understanding the pathophysiological mechanisms of age-related cerebrovascular alterations, alongside benefits of interventions such as physical activity. Therefore, our aims were …

us (code pays fourni par la source)

Reduction of generalized tonic–clonic seizures following vagus nerve stimulation therapy: CORE ‐ VNS Study 24‐month follow‐up

Ana Suller Martí, Ryan Verner, Mark R. Keezer, Andrea Andrade et autres

OBJECTIVE: Generalized tonic-clonic seizures (GTCS) are considered to be among the most devastating seizures due to increased health risks. Use of device-based therapies, such as vagus nerve stimulation (VNS), is common for those resistant to antiseizure medications and important for those in …

ca, gb (code pays fourni par la source)

Vagus nerve stimulation in Lennox–Gastaut syndrome: Twenty‐four‐month data and experience from the CORE ‐ VNS study

Paul D. Lyons, James W. Wheless, Ryan Verner, José Alexandre Ferreira et autres

OBJECTIVE: The drug-resistant epilepsy associated with Lennox-Gastaut syndrome (LGS) has a long-term effect on patients and is difficult to treat with conventional pharmacological and nonpharmacological therapies. Our objective is to demonstrate that adjunctive vagus nerve stimulation (VNS) can help manage the seizures …

us, gb (code pays fourni par la source)

Optimizing Time to Treatment with VNS: A CORE-VNS Registry Analysis of Prior Treatments (P7-1.011)

Ryan Verner, Arjune Sen, Rhys H. Thomas, Menaka Pasangy Paranathala et autres

Evaluate the time to treatment with VNS.

fr, gb, au (code pays fourni par la source)

Feasibility study of microburst VNS therapy in drug-resistant focal and generalized epilepsy

Cornelia Drees, Pegah Afra, Ryan Verner, Lesley Kaye et autres

BACKGROUND: Vagus nerve stimulation (VNS) at low frequencies (≤30 Hz) has been an established treatment for drug-resistant epilepsy (DRE) for over 25 years. OBJECTIVE: To examine the initial safety and efficacy performance of an investigational, high-frequency (≥250 Hz) VNS paradigm herein called …

us, gb, be (code pays fourni par la source)

Assumptions and statistical inference

Kathryn Nichol, Ryan Verner, Charles M. Gordon, Danielle Urry

To the Editors: Epilepsia has published two comparative effectiveness articles in the past 12 months that utilize systematic review and meta-analysis methodology to assess long-term seizure frequency reduction in focal and generalized onset epilepsies treated with neuromodulation.1, 2 The statistical assumptions in …

us (code pays fourni par la source)

The Proposed Multimodal Mechanism of Action of Cannabidiol (CBD) in Epilepsy: Modulation of Intracellular Calcium and Adenosine-mediated Signalling

Colin Stott, Kathryn Nichol, Nicholas A. Jones, Royston A. Gray et autres

gb (code pays fourni par la source)

The proposed multimodal mechanism of action of cannabidiol (CBD) in epilepsy: modulation of intracellular calcium and adenosine-mediated signaling (P5.5-007)

Kathryn Nichol, Colin Stott, Nicholas A. Jones, Royston A. Gray et autres

We present preclinical evidence summarizing CBD’s leading mechanisms of action in epilepsy.

gb (code pays fourni par la source)

Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

E. Martina Bebin, Daniel Checketts, Michael Chez, Robert Flamini et autres

BACKGROUND: Since 2014, patients with severe treatment-resistant epilepsies (TREs) have been receiving add-on cannabidiol (CBD) in an ongoing, expanded access program (EAP), which closely reflects clinical practice. We conducted an interim analysis of long-term efficacy and tolerability in patients with Lennox-Gastaut syndrome …

us, gb (code pays fourni par la source)

Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes

Henrik Jensen, Kathryn Nichol, Deborah Lee, Bjarke Ebert

Clobazam (CLB), a 1,5-benzodiazepine (BZD), was FDA-approved in October 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older. BZDs exert various CNS effects through allosteric modulation of GABAA receptors. The structurally distinct, 1,4-BZD …

dk, us (code pays fourni par la source)

Cardiovascular fitness is associated with altered cortical glucose metabolism during working memory in ε4 carriers

Sean P. Deeny, Jeanna Winchester, Kathryn Nichol, Stephen M. Roth et autres

BACKGROUND: The possibility that ɛ4 may modulate the effects of fitness in the brain remains controversial. The present exploratory FDG-PET study aimed to better understand the relationship among ɛ4, fitness, and cerebral metabolism in 18 healthy aged women (nine carriers, nine noncarriers) …

us (code pays fourni par la source)